

WE CLAIM:

1. A contrast agent for diagnostic imaging comprising:
- 5 a) an image-enhancing moiety (IEM);
b) a plasma protein binding moiety (PPBM); and
c) a blood half-life extending moiety (BHEM),
the contrast agent demonstrating at least about
10% binding to plasma proteins and, in a rat plasma
10 pharmacokinetic experiment, an area under the plasma
concentration versus time curve from 0 to 10 minutes
which is at least about 20% greater than that observed
for the combination of the IEM and the PPBM alone
without the BHEM.
- 15 2. The contrast agent according to claim 1,
wherein the image-enhancing moiety is selected from the
group consisting of organic molecules, metal ions,
salts or chelates, particles, iron particles, or
20 labeled peptides, proteins, polymers or liposomes.
3. The contrast agent according to claim 1,
wherein the image-enhancing moiety is a physiologically
compatible iron particle or metal chelate compound
25 consisting of one or more cyclic or acyclic organic
chelating agents complexed to one or more paramagnetic
metal ions with atomic numbers 21-29, 42, 44, or 57-83.
4. The contrast agent according to claim 1,
30 wherein the image-enhancing moiety is an iodinated
organic molecule or a physiologically compatible metal
chelate compound consisting of one or more cyclic or

10034522-122004

acyclic organic chelating agents complexed to one or more metal ions with atomic numbers 57 to 83.

5. The contrast agent according to claim 1,
5 wherein the image-enhancing moiety is gas-filled
bubbles or particles or a physiologically compatible
metal chelate compound consisting of one or more cyclic
or acyclic organic chelating agents complexed to one or
more metal ions with atomic numbers 21-29, 42, 44, or
10 57-83.

6. The contrast agent according to claim 1,
wherein the image-enhancing moiety consists of a
radioactive molecule.
15

7. The contrast agent according to claim 1,
wherein the image-enhancing moiety is a physiologically
compatible metal chelate compound consisting of one or
more cyclic or acyclic organic chelating agents
20 complexed to one or more metal ions with atomic numbers
27, 29, 31, 43, 47, 49, 75, 79, 82 or 83.

8. The contrast agent according to claim 1,
wherein the image-enhancing moiety is a physiologically
25 compatible metal chelate compound consisting of one or
more cyclic or acyclic organic chelating agents
complexed to Tc-99m.

9. The contrast agent according to claim 1,
30 wherein the image-enhancing moiety is an organic or
inorganic dye.

10034533-123001

10. The contrast agent according to claim 1, wherein the plasma protein binding moiety binds to human serum albumin.

5 11. The contrast agent according to claim 10, wherein the plasma protein binding moiety comprises an aliphatic group and/or at least one aryl ring.

10 12. The contrast agent according to claim 10, wherein the plasma protein binding moiety comprises a peptide containing hydrophobic amino acid residues and/or substituents with or without hydrophobic or hydrophilic termination groups.

15 13. The contrast agent according to claim 10, wherein the plasma protein binding moiety contains at least one aryl ring.

20 14. The contrast agent according to claim 10, wherein the plasma protein binding moiety contains at least two aryl rings held rigidly in a non-planar fashion.

25 15. The contrast agent according to claim 1, wherein the blood half-life extending moiety possesses one or more full or partial negative charges in aqueous solution at physiological pH wherein the negative charge cannot be partially or fully neutralized by covalent or coordinate covalent bonding to the image-
30 enhancing moiety.

10034522.12001

16. The contrast agent according to claim 1, wherein the contrast agent demonstrates at least about 50% binding to plasma proteins.

5 17. The contrast agent according to claim 1, wherein the contrast agent demonstrates at least about 80% binding to plasma proteins.

18. The contrast agent according to claim 1,
10 wherein the contrast agent demonstrates at least about 95% binding to plasma proteins.

19. The contrast agent according to claims 1, 16, 17 or 18, wherein the contrast agent
15 demonstrates, in a rat plasma pharmacokinetic experiment, an area under the plasma concentration versus time curve from 0 to 10 minutes which is at least about 40% greater than that observed for the combination of the IEM and the PPBM alone without the
20 BHEM.

20. The contrast agent according to claims 1, 16, 17 or 18, wherein the contrast agent demonstrates, in a rat plasma pharmacokinetic
25 experiment, an area under the plasma concentration versus time curve from 0 to 10 minutes which is at least about 70% greater than that observed for the combination of the IEM and the PPBM alone without the BHEM.

30

21. The contrast agent according to claims 1, 16, 17 or 18, wherein the contrast agent

10034522-122001

demonstrates, in a rat plasma pharmacokinetic experiment, an area under the plasma concentration versus time curve from 0 to 10 minutes which is at least about 100% greater than that observed for the combination of the IEM and the PPBM alone without the BHEM.

22. The contrast agent according to claims 1, 16, 17 or 18, wherein the contrast agent demonstrates, in a rat plasma pharmacokinetic experiment, an area under the plasma concentration versus time curve from 0 to 10 minutes which is from about 20% to about 100% greater than that observed for the combination of the IEM and the PPBM alone without the BHEM.

23. The contrast agent according to claims 1, 16, 17 or 18, wherein the contrast agent demonstrates, in a rat plasma pharmacokinetic experiment, an area under the plasma concentration versus time curve from 0 to 10 minutes which is from about 40% to about 100% greater than that observed for the combination of the IEM and the PPBM alone without the BHEM.

24. The contrast agent according to claims 1, 16, 17 or 18, wherein the contrast agent demonstrates, in a rat plasma pharmacokinetic experiment, an area under the plasma concentration versus time curve from 0 to 10 minutes which is from about 70% to about 100% greater than that observed for

10034523.122001

the combination of the IEM and the PPBM alone without the BHEM.

25. The contrast agent according to
5 claims 1, 16, 17 or 18, wherein the contrast agent demonstrates, in a rat plasma pharmacokinetic experiment, an area under the plasma concentration versus time curve from 0 to 10 minutes which is at least about 100% greater than that observed for the
10 combination of the IEM and the PPBM alone without the BHEM.

26. The contrast agent according to
claims 1, 16, 17 or 18, further comprising a targeting
15 moiety which allows the contrast agent to target a selected biological component.

27. The contrast agent according to
claim 26, wherein the targeting moiety is selected from
20 the group consisting of lipophilic substances, receptor ligands, and antibodies.

28. A method for extending blood half-life
of a diagnostic imaging contrast agent which comprises
25 an image-enhancing moiety and a plasma protein binding moiety and demonstrates at least about 10% binding to plasma proteins, comprising the step of incorporating into the contrast agent a blood half-life extending moiety in a position within the agent such that it does
30 not reduce the contrast agent's binding to plasma and such that the agent demonstrates, in a rat plasma pharmacokinetic experiment, an area under the plasma

10034522-122001

concentration versus time curve from 0 to 10 minutes
which is at least about 20% greater than that observed
for the combination of the image-enhancing moiety and
the protein plasma binding moiety alone without the
5 blood half-life extending moiety.

29. The method according to claim 28,
wherein the blood half-life extending moiety possesses
one or more full or partial negative charges in aqueous
10 solution at physiological pH and wherein the negative
charge or charges cannot be partially or fully
neutralized by covalent or coordinate covalent bonding
to the image-enhancing moiety.

30. The method according to claim 28,
wherein the area under the plasma concentration versus
time curve from 0 to 10 minutes of the contrast agent
is at least about 40% greater than that observed for
the combination of the image-enhancing moiety and the
20 protein plasma binding moiety alone without the blood
half-life extending moiety.

31. The method according to claim 28,
wherein the area under the plasma concentration versus
25 time curve from 0 to 10 minutes of the contrast agent
is at least about 70% greater than that observed for
the combination of the image-enhancing moiety and the
protein plasma binding moiety alone without the blood
half-life extending moiety.

30

32. The method according to claim 28,
wherein the area under the plasma concentration versus

10034522-120001

time curve from 0 to 10 minutes of the contrast agent is at least about 100% greater than that observed for the combination of the image-enhancing moiety and the protein plasma binding moiety alone without the blood
5 half-life extending moiety.

33. The method according to claim 28, wherein the area under the plasma concentration versus time curve of the contrast agent is from about 20% to
10 about 100% greater than that observed for the combination of the image-enhancing moiety and the protein plasma binding moiety alone without the blood half-life extending moiety.

34. The method according to claim 28, wherein the area under the plasma concentration versus time curve of the contrast agent is from about 40% to
15 about 100% greater than that observed for the combination of the image-enhancing moiety and the
20 protein plasma binding moiety alone without the blood half-life extending moiety.

35. The method according to claim 28, wherein the area under the plasma concentration versus
25 time curve of the contrast agent is from about 70% to about 100% greater than that observed for the combination of the image-enhancing moiety and the protein plasma binding moiety alone without the blood half-life extending moiety.

30

36. The method according to claim 28, wherein the area under the plasma concentration versus

10034522-122001

time curve from 0 to 10 minutes of the contrast agent is at least about 100% greater than that observed for the combination of the image-enhancing moiety and the protein plasma binding moiety alone without the blood half-life extending moiety.

37. A diagnostic imaging contrast agent comprising the following formula:

10




wherein IEM is an image-enhancing moiety,

L is a linker moiety,

15

BHEM is a blood half-life extending moiety possessing two or more electropositive hydrogen atoms, or two or more lone electron pairs that cannot be partially or fully neutralized by covalent or coordinate covalent bonding to the IEM, and is selected from the group consisting of sulfone, urea, thio-urea, amine, sulfonamide, carbamate, peptide, ester, carbonate, acetals and

25



30

where Z = P, W, Mo, or S

Y¹, Y² = O or S

35

Y³, Y⁴ = O, S or not present

R₂ = H, C₁₋₆ alkyl or not

present,

10034533-122001


PPBM is a plasma protein binding moiety comprising at least seven carbon atoms,

m can be equal to 0-4,

s, o, and p can be the same or different and equal to 1-4,

and q is at least one.

38. The contrast agent according to claim 37, wherein the BHEM is



or ester forms,

where Z = P, W, Mo, or S

Y¹, Y² = O or S

Y³, Y⁴ = O, S or not present

R₂ = H, C₁₋₆ alkyl or not

present.

39. The contrast agent according to claim 37, wherein the BHEM is phosphate or ester forms thereof.

40. The contrast agent according to claim 37, wherein the PPBM comprises at least 13 carbon atoms.

41. The contrast agent according to claim 37, wherein the PPBM comprises at least 18 carbon atoms.


42. The contrast agent according to claim 37, wherein the PPBM has a log P contribution of at least 2.0.

5 43. The contrast agent according to claim 37, wherein the PPBM has a log P contribution of at least 3.0.

10 44. The contrast agent according to claim 37, wherein the PPBM has a log P contribution of at least 4.0.

45. A diagnostic imaging contrast agent comprising the following formula:

15




20

wherein IEM is an image-enhancing moiety,

BHEM is a blood half-life extending moiety possessing two or more electropositive hydrogen atoms, or two or more lone electron pairs that cannot be partially or fully neutralized by covalent or coordinate covalent bonding to the IEM, and is selected from the group consisting of sulfone, urea, thio-urea, amine, sulfonamide, carbamate, peptide, ester, carbonate, acetals and

10034522-122001



or ester forms,

5

where Z = P, W, or Mo

10

$Y^1, Y^2 = O \text{ or } S$

$Y^3, Y^4 = O, S \text{ or not present}$


15 present,

$R_2 = H, C_{1-6} \text{ alkyl or not}$

PPBM is a plasma protein binding moiety
comprising at least seven carbon atoms,
s and o can be the same or different and
20 equal to 1-4,
and r is at least one.

46. The contrast agent according to
claim 45, wherein the BHEM is

25



or ester forms,

30

where Z = P, W, or Mo

$Y^1, Y^2 = O \text{ or } S$

35

$Y^3, Y^4 = O, S \text{ or not present}$

$R_2 = H, C_{1-6} \text{ alkyl or not}$

present.

1003453-122001

47. The contrast agent according to claim 45, wherein the BHEM is phosphate or ester forms thereof.

5 48. The contrast agent according to claim 45, wherein the PPBM comprises at least 13 carbon atoms.


10 49. The contrast agent according to claim 45, wherein the PPBM comprises at least 18 carbon atoms.

15 50. The contrast agent according to claim 45, wherein the PPBM has a log P contribution of at least 2.0.

20 51. The contrast agent according to claim 45, wherein the PPBM has a log P contribution of at least 3.0.

52. The contrast agent according to claim 45, wherein the PPBM has a log P contribution of at least 4.0.

25 53. A diagnostic imaging contrast agent comprising the following formula:




wherein IEM is an image-enhancing moiety,
L is a linker moiety,

10034522-122001

BHEM is a blood half-life extending moiety possessing two or more electropositive hydrogen atoms, or two or more lone electron pairs that cannot be partially or fully neutralized by covalent or
 5 coordinate covalent bonding to the IEM, and is selected from the group consisting of sulfone, urea, thio-urea, amine, sulfonamide, carbamate, peptide, ester, carbonate, acetals, SO_3^- or ester forms and

10



15

where Z = P, W, Mo, or S

20

$\text{Y}^1, \text{Y}^2 = \text{O or S}$

$\text{Y}^3, \text{Y}^4 = \text{O, S or not present}$

$\text{R}_2 = \text{H, C}_{1-6} \text{ alkyl or not}$


present,

25

PPBM is a plasma protein binding moiety comprising at least seven carbon atoms,
 m can be equal to 0-4,
 s and o can be the same or different and
 30 equal to 1-4.

54. The contrast agent according to claim 53, wherein the BHEM is

1003453-12001



where Z = P, W, Mo, or S

$Y^1, Y^2 = O \text{ or } S$

$Y^3, Y^4 = O, S \text{ or not present}$

$R_2 = H, C_{1-6} \text{ alkyl or not}$

present.

55. The contrast agent according to claim 53, wherein the BHEM is phosphate or ester forms thereof.

56. The contrast agent according to claim 53, wherein the PPBM comprises at least 13 carbon atoms.

57. The contrast agent according to claim 53, wherein the PPBM comprises at least 18 carbon atoms.


58. The contrast agent according to claim 53, wherein the PPBM has a log P contribution of at least 2.0.

59. The contrast agent according to claim 53, wherein the PPBM has a log P contribution of at least 3.0.


10034522.12001

60. The contrast agent according to claim 53, wherein the PPBM has a log P contribution of at least 4.0.

5 61. A diagnostic imaging contrast agent comprising:



or



10034522.12001

wherein M is a metal ion with an atomic number of 21-29, 42, 44 or 57-83,

R_1 - R_{11} and R_{16} can be the same or different and selected from the group consisting of H, PPBM, BHEM and C_{1-6} alkyl,

provided that at least one of R_1 - R_{11} or R_{16} is PPBM,


also provided that at least one of R_1 - R_{11} or R_{16} is BHEM,

R_{12} , R_{13} and R_{14} can be the same or different and selected from the group consisting of O^- and $N(H)R_{17}$,

$R_{15} = H, CH_2CH(OH)CH_3$, hydroxy alkyl or $CH(R_{16})COR_{12}$,

$R_{17} = H$ or C_{1-6} alkyl,

BHEM is a blood half-life extending moiety possessing two or more electropositive hydrogen atoms, or two or more lone electron pairs that cannot be partially or fully neutralized by covalent or coordinate covalent bonding to the IEM, and is selected from the group consisting of sulfone, urea, thio-urea, amine, sulfonamide, carbamate, peptide, ester, carbonate, acetals, COO^- or ester forms, SO_3^- or ester forms and



where $Z = P, W, Mo, \text{ or } S$

$Y^1, Y^2 = O \text{ or } S$

$Y^3, Y^4 = O, S \text{ or not present}$

10034522-122001

$R_2 = H, C_{1-6} \text{ alkyl or not present,}$

PPBM is a plasma protein binding moiety comprising at least seven carbon atoms.

5


62. The contrast agent according to claim 61, wherein M is selected from the group consisting of Gd(III), Fe(III), Mn(II), Mn(III), Cr(III), Cu(II), Dy(III), Tb(III), Ho(III), Er(III) and
10 Eu(III).

63. The contrast agent according to claim 62, wherein M is Gd(III).

15

64. The contrast agent according to any one of claims 61-63, wherein the BHEM is selected from the group consisting of COO⁻ or ester forms, SO₃⁻ or ester forms and

20



25

where $Z = P, W, Mo, \text{ or } S$

$Y^1, Y^2 = O \text{ or } S$

$Y^3, Y^4 = O, S \text{ or not present}$

30

$R_2 = H, C_{1-6} \text{ alkyl or not}$

present.

10034522-122001

65. The contrast agent according to any one of claims 61-63, wherein the PPBM comprises at least 13 carbon atoms.

5 66. The contrast agent according to any one of claims 61-63, wherein the PPBM comprises at least 18 carbon atoms.

10 67. The contrast agent according to any one of claims 61-63, wherein the PPBM has a log P contribution of at least 2.0.


15 68. The contrast agent according to any one of claims 61-63, wherein the PPBM has a log P contribution of at least 3.0.

20 69. The contrast agent according to any one of claims 61-63, wherein the PPBM has a log P contribution of at least 4.0.

70. A compound having the formula:


10034522-122001

-79-




MS-315

71. A compound having the formula:



MS-317

72. A compound having the formula:



MS-322

10034522-122001

5




74. A compound having the formula:




25

75. A compound having the formula:




MS-328

76. A compound having the formula:




77. A compound having the formula:




10034566-12001

78. A compound having the formula:




79. A compound having the formula:




10034522-122001

80. A compound having the formula:




81. A compound having the formula:




MS-326

10034522-123001

82. A compound having the formula:




83. A compound having the formula:




wherein PPBM is a plasma protein binding moiety comprising at least seven carbon atoms, and n can be equal to 1-4.

84. A compound having the formula:



wherein PPBM is a plasma protein binding moiety comprising at least seven carbon atoms, and n can be equal to 1-4.


85. A compound having the formula:



wherein n can be equal to 1-4.


1003462-1200

86. A compound having the formula:



wherein n can be equal to 1-4.


87. A compound having the formula:



wherein n can be equal to 1-4.


10034522 122001

88. A compound having the formula:



wherein n can be equal to 1-4.


89. A compound having the formula:



wherein n can be equal to 1-4.

10034522-122001


90. A compound having the formula:



10 wherein R comprises an aliphatic group and/or at least 1 aryl ring.

91. The compound according to claim 90, wherein R comprises a peptide containing hydrophobic
15 amino acid residues and/or substituents with or without hydrophobic or hydrophilic termination groups.

92. A compound having the formula:



25 wherein R comprises an aliphatic group and/or at least 1 aryl ring.

93. The compound according to claim 92, wherein R comprises a peptide containing hydrophobic
30 amino acid residues and/or substituents with or without hydrophobic or hydrophilic termination groups.

FOOZET-225001

94. A method for MRI imaging of a biological component comprising the step of administering a diagnostically effective amount of a contrast agent according to any one of claims 1, 37, 45, 53 or 61.

5

95. A method for ultrasound imaging of a biological component comprising the step of administering a diagnostically effective amount of a contrast agent according to any one of claims 1, 37, 45, 53 or 61.

10

96. A method for x-ray imaging of a biological component comprising the step of administering a diagnostically effective amount of a contrast agent according to any one of claims 1, 37, 45, 53 or 61.

15

97. A method for nuclear radiopharmaceutical imaging of a biological component comprising the step of administering a diagnostically effective amount of a contrast agent according to any one of claims 1, 37, 45, 53 or 61.

20

98. A method for ultraviolet/visible/infrared light imaging of a biological component comprising the step of administering a diagnostically effective amount of a contrast agent according to any one of claims 1, 37, 45, 53 or 61.

25

99. A pharmaceutical composition comprising a contrast agent according to any one of claims 1, 37, 45, 53 or 61 and a carrier, adjuvant or vehicle.

30

10034522-122001

100. The pharmaceutical composition according to claim 99, further comprising a free organic ligand or a pharmaceutically acceptable salt thereof.

5 101. The pharmaceutical composition according to claim 99, further comprising a free organic ligand or calcium, sodium, meglumine or combination salts thereof.

10 102. A method of administering a contrast agent according to any one of claims 1, 37, 45, 53 or 61, comprising the steps of:

- a) withdrawing a patient's blood into a syringe that contains the contrast agent;
- 15 b) mixing the blood and contrast agent in the syringe;
- c) and reinjecting the mixture into the patient.

10034522-122001

Ad
A8